Rhumbline Advisers Biomarin Pharmaceutical Inc Transaction History

Rhumbline Advisers

  • $105 Billion
  • Q2 2024

A detailed history of Rhumbline Advisers transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Rhumbline Advisers holds 551,553 shares of BMRN stock, worth $36.5 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
551,553
Previous 248,346 122.09%
Holding current value
$36.5 Million
Previous $21.7 Million 109.35%
% of portfolio
0.04%
Previous 0.02%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024
BUY
$74.43 - $92.22 $22.6 Million - $28 Million
303,207 Added 122.09%
551,553 $45.4 Million
Q1 2024

May 09, 2024
SELL
$83.81 - $99.0 $125,463 - $148,203
-1,497 Reduced 0.6%
248,346 $21.7 Million
Q4 2023

Feb 08, 2024
BUY
$76.22 - $98.51 $112,881 - $145,893
1,481 Added 0.6%
249,843 $24.1 Million
Q3 2023

Nov 09, 2023
SELL
$85.07 - $94.48 $295,788 - $328,506
-3,477 Reduced 1.38%
248,362 $22 Million
Q2 2023

Aug 08, 2023
BUY
$86.68 - $100.3 $3.19 Million - $3.69 Million
36,822 Added 17.13%
251,839 $21.8 Million
Q1 2023

May 11, 2023
SELL
$87.74 - $117.27 $427,995 - $572,043
-4,878 Reduced 2.22%
215,017 $20.9 Million
Q4 2022

Feb 14, 2023
BUY
$80.93 - $108.63 $801,854 - $1.08 Million
9,908 Added 4.72%
219,895 $22.8 Million
Q3 2022

Nov 10, 2022
BUY
$82.16 - $96.94 $1.42 Million - $1.68 Million
17,315 Added 8.99%
209,987 $17.8 Million
Q2 2022

Aug 11, 2022
BUY
$71.48 - $86.85 $2.09 Million - $2.54 Million
29,286 Added 17.92%
192,672 $16 Million
Q1 2022

May 12, 2022
BUY
$74.28 - $92.69 $547,666 - $683,403
7,373 Added 4.73%
163,386 $12.6 Million
Q4 2021

Feb 10, 2022
BUY
$71.72 - $91.47 $416,908 - $531,715
5,813 Added 3.87%
156,013 $13.8 Million
Q3 2021

Nov 12, 2021
SELL
$74.77 - $85.47 $1 Million - $1.14 Million
-13,392 Reduced 8.19%
150,200 $11.6 Million
Q2 2021

Aug 05, 2021
SELL
$75.51 - $84.79 $2.16 Million - $2.42 Million
-28,595 Reduced 14.88%
163,592 $13.7 Million
Q1 2021

May 06, 2021
SELL
$74.73 - $90.69 $890,034 - $1.08 Million
-11,910 Reduced 5.84%
192,187 $14.5 Million
Q4 2020

Feb 10, 2021
SELL
$72.61 - $90.2 $845,398 - $1.05 Million
-11,643 Reduced 5.4%
204,097 $17.9 Million
Q3 2020

Nov 12, 2020
SELL
$71.87 - $131.03 $1.07 Million - $1.96 Million
-14,933 Reduced 6.47%
215,740 $16.4 Million
Q2 2020

Aug 13, 2020
BUY
$79.55 - $124.22 $3.46 Million - $5.4 Million
43,446 Added 23.2%
230,673 $28.5 Million
Q1 2020

May 06, 2020
BUY
$71.37 - $96.85 $51,315 - $69,635
719 Added 0.39%
187,227 $15.8 Million
Q4 2019

Feb 05, 2020
BUY
$64.27 - $86.37 $368,202 - $494,813
5,729 Added 3.17%
186,508 $15.8 Million
Q3 2019

Oct 23, 2019
SELL
$67.4 - $85.11 $65,310 - $82,471
-969 Reduced 0.53%
180,779 $12.2 Million
Q2 2019

Aug 14, 2019
BUY
$80.35 - $93.9 $204,008 - $238,412
2,539 Added 1.42%
181,748 $15.6 Million
Q1 2019

May 01, 2019
SELL
$84.2 - $98.62 $143,308 - $167,851
-1,702 Reduced 0.94%
179,209 $15.9 Million
Q4 2018

Jan 31, 2019
SELL
$80.14 - $106.07 $751,552 - $994,724
-9,378 Reduced 4.93%
180,911 $15.4 Million
Q3 2018

Nov 07, 2018
SELL
$93.92 - $105.72 $372,298 - $419,074
-3,964 Reduced 2.04%
190,289 $18.5 Million
Q2 2018

Aug 06, 2018
SELL
$76.01 - $99.03 $611,120 - $796,201
-8,040 Reduced 3.97%
194,253 $18.3 Million
Q1 2018

May 02, 2018
SELL
$77.67 - $92.63 $483,340 - $576,436
-6,223 Reduced 2.98%
202,293 $16.4 Million
Q4 2017

Feb 09, 2018
SELL
$80.76 - $95.13 $125,016 - $147,261
-1,548 Reduced 0.74%
208,516 $18.6 Million
Q3 2017

Nov 06, 2017
BUY
$80.6 - $94.95 $16.9 Million - $19.9 Million
210,064
210,064 $19.6 Million

Others Institutions Holding BMRN

# of Institutions
621
Shares Held
183M
Call Options Held
1.63M
Put Options Held
1.2M
View Full List

About BIOMARIN PHARMACEUTICAL INC

BMRN Quotes by TradingView
  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.3B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email